This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Ironically, a recent FDA safety communication points to a potential way out of this dilemma. In this safety communication, FDA advises the public as follows: If you test negative and have COVID-19 symptoms , you test again 48 hours later for a total of two tests.
The current unmet need, the benefit of treatment with Rexulti, and a reasonable safety profile persuaded Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s MedicalSchool, to give a positive vote. Rexulti is an atypical antipsychotic.
Physicians associated with the Department of Psychiatry at Harvard MedicalSchool reported on six patients who suddenly developed an: “intense violent suicidal preoccupation after 2-7 weeks of fluoxetine [Prozac] treatment.” . “But in February 1990 an article appeared in the American Journal of Psychiatry (Feb.
I DID NOT consent to receive an off-label drug with NO evidence of benefit with a single dose. The British Medical Association (BMA) also blasted the decision as “unreasonable and totally unfair”. Just received this email cancelling my 2nd dose of the Pfizer vaccine. On the basis of UK government guidance yesterday.
I DID NOT consent to receive an off-label drug with NO evidence of benefit with a single dose. The British Medical Association (BMA) also blasted the decision as “unreasonable and totally unfair”. Just received this email cancelling my 2nd dose of the Pfizer vaccine. On the basis of UK government guidance yesterday.
In an email to this news service, João Conde, PhD, professor at NOVA MedicalSchool, Universidade NOVA de Lisboa, said advances like the mRNA vaccines serve as a testament to the breakthroughs made by science over decades of research at the junction of genetics and nanomedicine. Please check your email to download the Report.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content